The case for & against
Bull & Bear analysis
Bullish
Connect Biopharma Holdings Ltd (NASDAQ: CNTB) is a clinical-stage biopharmaceutical company focusing on developing therapies for T-cell-driven inflammatory diseases. The company is advancing its lead product, rademikibart, an anti-interleukin-4-receptor alpha antibody, aimed at improving treatment outcomes for asthma and chronic obstructive pulmonary disease (COPD). Operating globally, with facilities in the U.S., China, and Australia, Connect Biopharma is strategically positioned within the evolving biopharmaceutical landscape and is witnessing increasing demand for innovative treatments.
Bull says
- ↑Analysts rate CNTB a Strong Buy with $7 average PT (179% upside).
- ↑Revenue forecast to climb from $4.82M this year to $10.54M next year.
- ↑Phase IIb trial top-line results for CBP201 expected in Q4 ’21.
- ↑$313.5M cash and equivalents post-IPO funds operations for ≥12 months.
- ↑High institutional ownership signals strong hedge-fund confidence.
- ↑High growth score and strong momentum factors support upside.
Bear says
- ↓Cash burn rose to $39.1M in H1 2021 from $7.7M a year ago.
- ↓Approval in China hinges on standalone study completion, delaying breakthrough status.
- ↓Dupilumab’s established market share may limit CBP201 uptake.
- ↓Negative profitability and earnings yield metrics raise viability concerns.
- ↓Elevated share volatility may deter investors and complicate forecasts.
- ↓Weak profitability factors and high volatility underscore downside risks.
Earnings Call · Q2 2021 · Mgmt. Guidance
Updated 07-14-2026bullish
Transcript signals
Bull points
- we have advanced two internally discovered molecules into Phase II clinical development.
- In March, we completed an IPO listing of our American depository shares on the NASDAQ Global Select Market, raising net proceeds of approximately $204.5 million, which significantly enhanced our cash balance, enabling us to invest in and advance our pipeline.
- we believe that CBP201 may have three potential advantages over the current standard of care.
Bear points
- During the period ended June 30th, 2021 net cash use and operating activities was RMB $252.8 million or US dollar $39.1 million compared to RMB 53 million in the prior year period. The increase in the use of cash was due primarily to increased R&D and administrative expenses, as well as the expansion of our clinical trials and development of additional pipeline therapies.
Read full transcript analysis ›